Stockscreener 앱 받기
119.41
8.28%
9.13
시간 외 거래:
119.05
-0.36
-0.30%
전일 마감가:
$110.28
열려 있는:
$115.22
하루 거래량:
10.60M
Relative Volume:
1.38
시가총액:
$148.54B
수익:
$28.86B
순이익/손실:
$6.31B
주가수익비율:
23.79
EPS:
5.02
순현금흐름:
$9.37B
1주 성능:
+5.50%
1개월 성능:
+7.52%
6개월 성능:
+24.33%
1년 성능:
+57.97%
1일 변동 폭
$114.80
$121.38
1주일 범위
$108.54
$121.38
52주 변동 폭
$72.43
$121.38
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
119.41 | 137.18B | 28.86B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences’ Twice-Yearly HIV Prevention Drug Recommended for Approval by European Medicines Agency - Insider Monkey
Gilead Sciences' Strategic Momentum with Yeztugo and HIV Portfolio Growth: A Cornerstone for Long-Term Value Creation - AInvest
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish - MSN
Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences (GILD) Rises on Raised 2025 Guidance and $6B Buyback Is Its Outlook Reinvigorated? - simplywall.st
Gilead trims assets partnered with Novo Nordisk, Arcus from pipeline - FirstWord Pharma
Gilead Sciences Surges 8.28% On Bullish Breakout With Heavy Volume - AInvest
Earnings Season Boosts Confidence: Gilead and Expedia Lead Strong Corporate Results - FinancialContent
These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More - Barron's
Why Gilead Stock Surged 8%, Flirting With A Breakout - Investor's Business Daily
Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook - Invezz
Gilead Rallies: Bullish Surge Continues! - timothysykes.com
Gilead Sciences stock price target raised to $140 from $126 at BofA - Investing.com Australia
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Gains Ground As Gilead Sciences Soars 8% - FXEmpire
Gilead Sciences jumps after Q2 beat; Truist upgrades to Buy - MSN
Gilead Sciences’ Yeztugo Projected to Reach $5 Billion in Global Sales by 2031 - geneonline.com
Earnings Season Highlights: Gilead Sciences and Expedia Group Post Strong Results - FinancialContent
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details - The Economic Times
Gilead’s Yeztugo sales “ahead of expectations” following launch - Yahoo Finance
Gilead Sciences’ Breast Cancer Study: A Potential Game-Changer in Oncology? - TipRanks
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today - Yahoo Finance
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Gilead Sciences Stock Surges 9% on Strong Q2 Earnings - AInvest
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
Gilead culls Novo-partnered MASH candidate and 2 cancer assets - Fierce Biotech
Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales - Fierce Pharma
Gilead Sciences Up Over 8%, on Track for Highest Close Since June 2015 — Data Talk - Morningstar
Why Is Gilead Sciences Stock Surging Friday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead's Optimistic Relaxed CAR T Safety Monitoring Could Help Sluggish Yescarta, Tecartus Q2 Sales - Precision Medicine Online
Gilead Sciences: Is There Momentum to Sustain Market Buzz? - StocksToTrade
Shareholders strongly echo Gilead’s successful quarter claims - The Pharma Letter
Gilead Sciences stock price target raised to $98 from $96 at RBC Capital - Investing.com
Truist Securities Upgrades Gilead Sciences to Buy From Hold, Hikes Price Target to $127 From $108 - MarketScreener
UBS Raises Price Target on Gilead Sciences to $112 From $108, Maintains Neutral Rating - MarketScreener
Gilead Sciences stock price target raised to $115 from $110 at TD Cowen - Investing.com Canada
Gilead Sciences Reports Strong Q2 Earnings, Beats Wall Street EstimatesNews and Statistics - IndexBox
Baird Adjusts Price Target on Gilead Sciences to $108 From $100, Maintains Neutral Rating - MarketScreener
JPMorgan Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Overweight Rating - MarketScreener
BMO Capital Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Outperform Rating - MarketScreener
Gilead Stock Showered With Upgrades, Price Target Hikes After Upbeat Q2, Guidance Lift: Retail’s Turned Exuberant - Stocktwits
Goldman Sachs Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Neutral Rating - MarketScreener
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties - BioSpace
Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs - insights.citeline.com
Truist Securities upgrades Gilead Sciences stock to Buy on HIV strength - Investing.com Canada
Gilead Sciences stock price target raised to $112 from $108 at UBS - Investing.com Canada
Stock Movers: LMT, Monster, Gilead - Bloomberg.com
Street View: Optimistic about launch of Gilead's twice-yearly HIV prevention shot - TradingView
Gilead Sciences (GILD) Soars 3.73% on Strong Q2 Earnings - AInvest
Gilead lifts 2025 forecast as HIV treatment sales strengthen - MSN
These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences - MSN
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.63%
자본화:
|
볼륨(24시간):